Healthcare Market Access: Indonesia
The report provides in-depth information on:
- Country Landscape – This section covers information on the prevailing economic environment in the country and dwells on both macro and micro economic indicators. The demographic profile of the country highlights the growing importance of middle class and increasing access to internet. It also captures the political landscape along with the opportunities and challenges presented by the country.
- Healthcare infrastructure – Insightful review of the country’s healthcare system and health status with key health indicators are presented in this section. Moreover, healthcare expenditure and share of public and private sectors are prominently discussed in the section. The profiles of major hospitals and the number of healthcare personnel in the country are also comprehensively covered.
- Overview of Pharmaceutical Market – This section depicts the pharmaceutical market in terms of size, growth, product mix and key players operating in the country. A special emphasis has been laid on the key drivers and barriers impacting the pharmaceutical market of the country. Furthermore, the profiles of major diseases with high burden for the country have been covered.
- Market Access: This section dwells on the role and importance of various stakeholders in product commercialization process and gatekeepers holding the key to the access for pharmaceutical products. Various regulatory aspects crucial for approval and marketing of various categories of pharmaceutical products have been captured comprehensively. In addition, detailed analysis of pricing and reimbursement landscape along with the prescribing policies and influence, price build-up and trends and various drug lists impacting reimbursement is covered.
1. COUNTRY LANDSCAPE
1.1 Economic environment
1.2 Economic indicators
1.2.1 Gross domestic product
1.2.2 Gross national income
1.2.3 Inflation
1.2.4 Foreign exchange reserves
1.2.5 Current account balance
1.2.6 Government gross debt
1.2.7 Exchange rate
1.2.8 Foreign direct investment
1.2.9 Trade balance
1.3 Demographics
1.3.1 Population
1.3.2 Growth of middle class
1.3.3 Education and literacy
1.3.4 Access to internet
1.3.5 Employment
1.4 Political structure and environment
1.4.1 Political history
1.4.2 Political structure
1.4.3 Current government
1.5 Trade associations
1.5.1 International Pharmaceutical Manufacturers Group
1.5.2 Indonesian Pharmaceutical Association
1.6 Opportunities and challenges
1.6.1 Opportunities
1.6.2 Challenges
2 HEALTHCARE INFRASTRUCTURE
2.1 Healthcare system
2.2 Health status
2.2.1 Life expectancy
2.2.2 Mortality rate
2.2.3 Total fertility rate
2.3 Healthcare policy
2.4 Healthcare financing and expenditure
2.4.1 Healthcare expenditure as a percentage of GDP
2.5 Major components of healthcare spending
2.6 Shares of the public and private sectors
2.7 Pharmaceutical expenditure
2.8 Spending in pharmaceutical R&D
2.9 Health insurance
2.10 Hospital sector
2.10.1 Major hospital profiles
2.10.1.1 Siloam Hospital Group
2.10.1.2 Eka Hospital
2.10.1.3 Santosa Hospital
2.10.1.4 Dr. Cipto Mangunkusumo Hospital (RSCM)
2.10.1.5 Premier Hospital – Ramsey Healthcare Group
2.10.1.6 Central Army Gatot Subroto Hospital
2.11 Healthcare personnel
3 OVERVIEW OF PHARMACEUTICAL MARKET
3.1 Market overview
3.2 Industry structure
3.3 Market segments
3.4 Opportunities and challenges
3.4.1 Opportunities
3.4.2 Challenges
3.5 Major players
3.5.1 Kalbe Farma
3.5.2 Sanbe Farma
3.5.3 Kimia Farma
3.5.4 PT Merck Tbk
3.5.5 PT Novartis Indonesia
3.5.6 Sanofi Group Indonesia
3.5.7 PT SOHO Industri Pharmasi
3.6 Key products
3.7 Leading therapeutic segments
3.8 Supply channel
3.8.1 Distribution / wholesale
3.8.2 Retail
3.9 Sales and marketing
3.10 FDI in pharmaceutical industry
3.12 Events
3.13 Major diseases
3.13.1 Stroke
3.13.2 Cancer
3.13.3 Tuberculosis
3.13.4 Diarrhea
3.13.5 Diabetes mellitus
3.13.6 Ischemic heart disease
4 MARKET ACCESS
4.1 Stakeholder landscape
4.2 Regulatory landscape
4.2.1 Regulatory agencies
4.2.2 Market authorization for pharmaceutical products
4.2.3 Clinical trial regulations
4.2.4 Licensing process for pharmaceutical manufacturing
4.2.5 Post-marketing regulations
4.2.6 Labeling and advertising
4.2.7 Licensing process for pharmaceutical imports
4.2.9 Intellectual property rights
4.2.9.1 Patent
4.3 Pricing
4.3.1 Pricing system
4.3.2 Pricing policy
4.3.3 Price trends
4.3.4 Discounts and margins
4.4 Reimbursement landscape
4.4.1 Reimbursement process
4.4.2 Insurance providers
4.4.2.1 Public insurance
4.4.2.2 Private insurance
4.4.3 Co-payments
4.5 Prescribing and dispensing
4.5.1 Prescribing guidelines
4.5.2 Prescribing influences
4.5.3 Dispensing
4.6 Reimbursement drug lists
4.6.1 National List of Essential Medicines (NLEM)
4.6.2 Daftar Plafon Harga Obat (DPHO)
4.6.3 National formulary (Fornas)
4.7 Drug procurement
4.8 Hospital formulary
5 APPENDIX
5.1 Glossary
5.2 Sources
5.3 Methodology
5.3.1 Secondary research
5.3.2 Primary research
5.3.3 Data validation
5.4 Disclaimer
5.5 Contact us
1.1 Economic environment
1.2 Economic indicators
1.2.1 Gross domestic product
1.2.2 Gross national income
1.2.3 Inflation
1.2.4 Foreign exchange reserves
1.2.5 Current account balance
1.2.6 Government gross debt
1.2.7 Exchange rate
1.2.8 Foreign direct investment
1.2.9 Trade balance
1.3 Demographics
1.3.1 Population
1.3.2 Growth of middle class
1.3.3 Education and literacy
1.3.4 Access to internet
1.3.5 Employment
1.4 Political structure and environment
1.4.1 Political history
1.4.2 Political structure
1.4.3 Current government
1.5 Trade associations
1.5.1 International Pharmaceutical Manufacturers Group
1.5.2 Indonesian Pharmaceutical Association
1.6 Opportunities and challenges
1.6.1 Opportunities
1.6.2 Challenges
2 HEALTHCARE INFRASTRUCTURE
2.1 Healthcare system
2.2 Health status
2.2.1 Life expectancy
2.2.2 Mortality rate
2.2.3 Total fertility rate
2.3 Healthcare policy
2.4 Healthcare financing and expenditure
2.4.1 Healthcare expenditure as a percentage of GDP
2.5 Major components of healthcare spending
2.6 Shares of the public and private sectors
2.7 Pharmaceutical expenditure
2.8 Spending in pharmaceutical R&D
2.9 Health insurance
2.10 Hospital sector
2.10.1 Major hospital profiles
2.10.1.1 Siloam Hospital Group
2.10.1.2 Eka Hospital
2.10.1.3 Santosa Hospital
2.10.1.4 Dr. Cipto Mangunkusumo Hospital (RSCM)
2.10.1.5 Premier Hospital – Ramsey Healthcare Group
2.10.1.6 Central Army Gatot Subroto Hospital
2.11 Healthcare personnel
3 OVERVIEW OF PHARMACEUTICAL MARKET
3.1 Market overview
3.2 Industry structure
3.3 Market segments
3.4 Opportunities and challenges
3.4.1 Opportunities
3.4.2 Challenges
3.5 Major players
3.5.1 Kalbe Farma
3.5.2 Sanbe Farma
3.5.3 Kimia Farma
3.5.4 PT Merck Tbk
3.5.5 PT Novartis Indonesia
3.5.6 Sanofi Group Indonesia
3.5.7 PT SOHO Industri Pharmasi
3.6 Key products
3.7 Leading therapeutic segments
3.8 Supply channel
3.8.1 Distribution / wholesale
3.8.2 Retail
3.9 Sales and marketing
3.10 FDI in pharmaceutical industry
3.12 Events
3.13 Major diseases
3.13.1 Stroke
3.13.2 Cancer
3.13.3 Tuberculosis
3.13.4 Diarrhea
3.13.5 Diabetes mellitus
3.13.6 Ischemic heart disease
4 MARKET ACCESS
4.1 Stakeholder landscape
4.2 Regulatory landscape
4.2.1 Regulatory agencies
4.2.2 Market authorization for pharmaceutical products
4.2.3 Clinical trial regulations
4.2.4 Licensing process for pharmaceutical manufacturing
4.2.5 Post-marketing regulations
4.2.6 Labeling and advertising
4.2.7 Licensing process for pharmaceutical imports
4.2.9 Intellectual property rights
4.2.9.1 Patent
4.3 Pricing
4.3.1 Pricing system
4.3.2 Pricing policy
4.3.3 Price trends
4.3.4 Discounts and margins
4.4 Reimbursement landscape
4.4.1 Reimbursement process
4.4.2 Insurance providers
4.4.2.1 Public insurance
4.4.2.2 Private insurance
4.4.3 Co-payments
4.5 Prescribing and dispensing
4.5.1 Prescribing guidelines
4.5.2 Prescribing influences
4.5.3 Dispensing
4.6 Reimbursement drug lists
4.6.1 National List of Essential Medicines (NLEM)
4.6.2 Daftar Plafon Harga Obat (DPHO)
4.6.3 National formulary (Fornas)
4.7 Drug procurement
4.8 Hospital formulary
5 APPENDIX
5.1 Glossary
5.2 Sources
5.3 Methodology
5.3.1 Secondary research
5.3.2 Primary research
5.3.3 Data validation
5.4 Disclaimer
5.5 Contact us
